维普中文期刊产品整合服务
1篇 您的检索式:作者名="Lydia Usha"
    题名 作者 年代 出处 被引量
1TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient:A case report and literature review显示文摘Adalimumab(ADA)is a tumor necrosis factor(TNF)inhibitor,used for the treatment of inflammatory bowel disease.Previous studies have reported an increased risk of cancer following exposure to TNF inhibitors,but little has been reported for patients with cancer receiving TNF-inhibitor treatment.We present a female patient with metastatic breast cancer and ulcerative colitis(UC)who was treated with ADA.A 54-year-old African American female with a past history of left-sided breast cancer(BC)diagnosed at age 30 was initially treated with left-breast lumpectomy,axillary dissection,followed by chemotherapy and radiation therapy.Years after initial diagnosis,she developed recurrent,bilateral BC and had bilateral mastectomy.Subsequent restaging computed tomography(CT)scan demonstrated distant metastases to the bone and lymph nodes.Three years into her treatment of metastatic breast cancer,she was diagnosed with UC by colonoscopy.Her UC was not controlled for 5 mo with 5-aminosalicylates.Subcutaneous ADA was started and resulted in dramatic improvement of UC.Four months after starting ADA,along with ongoing chemotherapy,restaging CT scan showed resolution of the previously seen metastatic lymph nodes.Bone scan and follow-up positron emission tomography/CT scans performed every 6 mo indicated the stability of healed metastatic bone lesions for the past 3 years on ADA.While TNF-αinhibitors could theoretically promote further metastases in patients with prior cancer,this is the first report of a patient with metastatic breast cancer in whom the cancer has remained stable for 3 years after ADA initiation for UC.Ruwaida Ben Musa Lydia Usha John Hibbeln Ece A Mutlu 2014World Journal of Gastroenterology2014,20,19:2
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费